Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: atreca.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $17.00 → $14.00 | Buy | Stifel |
4 - Atreca, Inc. (0001532346) (Issuer)
DEFM14A - Atreca, Inc. (0001532346) (Filer)
PREM14A - Atreca, Inc. (0001532346) (Filer)
15-12G - Atreca, Inc. (0001532346) (Filer)
S-8 POS - Atreca, Inc. (0001532346) (Filer)
S-8 POS - Atreca, Inc. (0001532346) (Filer)
S-8 POS - Atreca, Inc. (0001532346) (Filer)
S-8 POS - Atreca, Inc. (0001532346) (Filer)
S-8 POS - Atreca, Inc. (0001532346) (Filer)
DEFA14A - Atreca, Inc. (0001532346) (Filer)
DEFA14A - Atreca, Inc. (0001532346) (Filer)
Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously
Robert W. Baird resumed coverage of Atreca with a rating of Outperform and set a new price target of $27.00 from $30.00 previously
Jefferies initiated coverage of Atreca with a rating of Buy and set a new price target of $30.00
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (NASDAQ:BCEL) to acquire a collection of antibody-related assets and materials. "We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. Under the terms of the ass
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (NASDAQ:IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. "We are pleased to announce this asset purchase agreement with Immunome, a com
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. "Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding no
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, which represented approximately $13 million of annual expenditures. In addition, Herb Cross, Chief Financial Officer, will depart the Company on September 22, 2023, to pursue an external opportunity. Mr.
Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2023, and announced a corporate reorganization to reduce expenses and extend its cash runway. As part of the reorganization, Atreca will be undertaking cost-saving meas
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles, presented
SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2023 and provided an overview of recent developments. "In the first quarter of 2023 we continued to advance both ATRC-101 and our preclinical programs. The additional data from the ongoing Phase 1b study of ATRC-101 that we reported in March will help inform our anticipated go / no-go decision for Phase 2 development, which remains on-track for la
SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that data from the Phase 1b study of ATRC-101 will be presented during an oral abstract session at the American Society of Clinical Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois. Details of the presentation are as follows: Abstract Title: Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.Abstract Number: 2505Session: Developmental Therapeuti
SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion on T-Cells and "Informative B-Cells" at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20th, 2023, from 10:00 to 10:45 AM ET. A live webcast of the panel will be available to registered conference attendees through the conference portal. Atreca management will also be partici
ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. "Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101. As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, a
- Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company's growth and further enhance its ability to build an integrated technology platform for the development and scaling of regenerative medicines. "We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to
SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. "Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team," said John Orwin, Chief Executive Officer of Atreca. "Our discovery platform has proven to be highly productive in generating promising tumor-sele
SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors. "We are pleased to be expanding our Board of Directors with the addition of two experienced and accomplished biopharmaceutical executives" said John Orwin, Chief Executive Officer. "Together,
ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati
SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc
Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C
SAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a virtual R&D Day on Tuesday, April 5, 2022, at 4:15 p.m. EDT, focused on the Company's preclinical pipeline programs in oncology. Presenters: John Orwin, Chief Executive OfficerTito Serafini, PhD, Chief Strategy Officer and FounderDaniel Emerling, PhD, Senior Vice President, Research and Co-FounderAmy Manning-Bog, PhD, Vice President, Translational SciencesShaun Lippow, PhD, Vice Presi
Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical activity observed in multiple tumor types and significantly associated with ATRC-101 target expression; target diagnostic validated and planning for participant selection based on target expression ATRC-101 has been well-tolerated with no dose-limiting toxicities observed Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EST SAN CARLOS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will report fourth quarter 2021 financial results and members of the company's management team will host a year-end conference call, which will include an update on progress in the ongoing ATRC-101 clinical program, on Thursday, March 3, 2022, at 4:30 p.m. EST. To access the live conference call by telephone, please dial (800) 373-6606 (Domestic) or 409-937-8918 (International). The conference
SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a webinar to present initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types on Thursday, July 29, 2021, at 8:00 a.m. ET. Conference Call and Webcast Information The live webcast, including slides, can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events
SC 13G - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
SC 13G/A - Atreca, Inc. (0001532346) (Subject)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
3 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)
4 - Atreca, Inc. (0001532346) (Issuer)